Ono Pharmaceutical Co Ltd
TSE:4528

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
TSE:4528
Watchlist
Price: 1 606 JPY -0.12% Market Closed
Market Cap: 754.2B JPY
Have any thoughts about
Ono Pharmaceutical Co Ltd?
Write Note

Ono Pharmaceutical Co Ltd
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ono Pharmaceutical Co Ltd
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Ono Pharmaceutical Co Ltd
TSE:4528
Cash Interest Paid
ÂĄ339m
CAGR 3-Years
68%
CAGR 5-Years
42%
CAGR 10-Years
37%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash Interest Paid
ÂĄ93B
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
33%
Daiichi Sankyo Co Ltd
TSE:4568
Cash Interest Paid
ÂĄ1.6B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
5%
Otsuka Holdings Co Ltd
TSE:4578
Cash Interest Paid
ÂĄ4.1B
CAGR 3-Years
13%
CAGR 5-Years
0%
CAGR 10-Years
10%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash Interest Paid
ÂĄ81m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ono Pharmaceutical Co Ltd
Glance View

Market Cap
754.4B JPY
Industry
Pharmaceuticals

In the bustling city of Osaka, Japan, Ono Pharmaceutical Co., Ltd. stands as a venerable institution with roots tracing back over three centuries. Origination in 1717 as an apothecary, Ono has evolved into a leading biopharmaceutical company renowned for its pioneering work in immunology. They have a rich history of innovation in drug development, marked by the success of their groundbreaking anti-cancer agent, Opdivo. This is a product of their intensive research and development in the field of immune checkpoint inhibitors, a class of drugs that revolutionizes cancer treatment by bolstering the body's natural defenses to combat malignant cells. Ono’s commitment to R&D, underscored by substantial investment, remains its cornerstone, transforming complex scientific concepts into therapeutic products. The essence of Ono Pharmaceutical’s business model rests on its adeptness at translating scientific excellence into commercial success. They operate within two primary segments: pharmaceutical products and clinical testing-related services. The pharmaceutical segment, the larger of the two, is the engine driving revenue through the development and global distribution of prescription drugs, focusing extensively on treatments in the central nervous system, cancer, and infectious diseases. Ono leverages strategic alliances with global pharmaceutical giants, facilitating broader distribution networks and shared research endeavors, thus amplifying their market presence and financial returns. Their strategy encapsulates a cycle of discovery, development, and commercialization, continually striving to deliver innovative medicinal solutions that enhance the quality of life worldwide.

Intrinsic Value
2 699.78 JPY
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Ono Pharmaceutical Co Ltd's Cash Interest Paid?
Cash Interest Paid
339m JPY

Based on the financial report for Sep 30, 2024, Ono Pharmaceutical Co Ltd's Cash Interest Paid amounts to 339m JPY.

What is Ono Pharmaceutical Co Ltd's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
37%

Over the last year, the Cash Interest Paid growth was 285%. The average annual Cash Interest Paid growth rates for Ono Pharmaceutical Co Ltd have been 68% over the past three years , 42% over the past five years , and 37% over the past ten years .

Back to Top